FDA approves first Stelara biosimilar, Wezlana
European Pharmaceutical Review
NOVEMBER 2, 2023
The US Food and Drug Administration ( FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). The evidence also demonstrated that Wezlana met the other legal requirements to be interchangeable with Stelara at the pharmacy level, without consulting the prescriber.
Let's personalize your content